SCHEMBL4817800

SCHEMBL4817800

O=C(Nc1cc2ccc(O)cc2oc1=O)c1cccc(Cl)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.76
POLB P06746 1/20 0.65
MAOB P27338 6/20 0.58
ACHE P22303 3/20 0.58
PKM P14618 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
MIF P14174 2/20 0.56
ALDH1A1 P00352 4/20 0.55
MAPT P10636 3/20 0.55
HPGD P15428 2/20 0.55
LMNA P02545 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KCNMA1 Q12791 1/20 0.52
MAOA P21397 1/20 0.52
KDM4E B2RXH2 1/20 0.49
ADORA3 P0DMS8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4819228 0.86 POLB (0.77) TP53POLBMAOBACHEPKM
SCHEMBL4819273 0.86 TP53 (1.00) TP53POLBMAOBACHEPKM
SCHEMBL4820635 0.86 TP53 (0.76) TP53POLBMAOBACHEPKM
SCHEMBL4818996 0.84 MAOB (0.74) TP53POLBMAOBACHEPKM
SCHEMBL4821180 0.83 TP53 (0.79) TP53POLBMAOBACHEPKM
SCHEMBL4819215 0.83 MAPT (0.74) TP53POLBMAOBACHEPKM
SCHEMBL4820220 0.82 TP53 (0.69) TP53POLBMAOBACHEPKM
SCHEMBL4821425 0.80 TP53 (0.86) TP53POLBMAOBACHEPKM
SCHEMBL4820097 0.80 TP53 (0.70) TP53POLBMAOBACHEPKM
SCHEMBL4816078 0.79 TP53 (1.00) TP53POLBMAOBACHEPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7411076-B2 such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-08-12 US disclosed
US-20050054717-A1 Coumarin derivative INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054717-A1 Coumarin derivative ERCC2, ERCC4, DDB1 TP53 81/4885POLB 290/4885MAOB 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.